A
Ankur Pandya
Researcher at Harvard University
Publications - 106
Citations - 4365
Ankur Pandya is an academic researcher from Harvard University. The author has contributed to research in topics: Cost effectiveness & Medicine. The author has an hindex of 26, co-authored 86 publications receiving 3531 citations. Previous affiliations of Ankur Pandya include NewYork–Presbyterian Hospital & Cornell University.
Papers
More filters
Posted Content
The Global Economic Burden of Noncommunicable Diseases
David E. Bloom,Elizabeth T. Cafiero,Eva Jané-Llopis,Shafika Abrahams-Gessel,Lakshmi Reddy Bloom,Sana F. Fathima,Andrea B. Feigl,Tom Gaziano,Ali Hamandi,Mona Mowafi,Danny O’Farrell,Emre Özaltin,Ankur Pandya,Klaus Prettner,Larry Rosenberg,Benjamin Seligman,Adam Z. Stein,Cara Weinstein,Jonathan Weiss +18 more
TL;DR: New estimates of the global economic burden of non-communicable diseases in 2010 are developed, and the size of the burden through 2030 is projected, to capture the thinking of the business community about the impact of NCDs on their enterprises.
Journal ArticleDOI
Carotid Plaque MRI and Stroke Risk A Systematic Review and Meta-analysis
Ajay Gupta,Hediyeh Baradaran,Andrew D. Schweitzer,Hooman Kamel,Ankur Pandya,Diana Delgado,Allison Dunning,Alvin I. Mushlin,Pina C. Sanelli +8 more
TL;DR: The presence of intraplaque hemorrhage, lipid-rich necrotic core, and thinning/rupture of the fibrous cap on MRI of carotid plaque is associated with increased risk of future stroke or transient ischemic attack in patients with carOTid atherosclerotic disease.
Journal ArticleDOI
Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease
TL;DR: In this microsimulation model of US adults aged 45 to 75 years [corrected], the current 10-year ASCVD risk threshold used in the ACC/AHA cholesterol treatment guidelines has an acceptable cost-effectiveness profile (ICER, $37,000/QALY), but more lenient ASCVD thresholds would be optimal using cost-Effectiveness thresholds of $100,000 or lower (≥4.0% risk threshold).
Journal ArticleDOI
Plaque Echolucency and Stroke Risk in Asymptomatic Carotid Stenosis A Systematic Review and Meta-Analysis
Ajay Gupta,Kartik Kesavabhotla,Hediyeh Baradaran,Hooman Kamel,Ankur Pandya,Ashley E. Giambrone,Drew Wright,Kevin J. Pain,Edward E. Mtui,Jasjit S. Suri,Pina C. Sanelli,Alvin I. Mushlin +11 more
TL;DR: The presence of ultrasound-determinedCarotid plaque echolucency provides predictive information in asymptomatic carotid artery stenosis beyond luminal stenosis, but the magnitude of the increased risk is not sufficient on its own to iden tify patients likely to benefit from surgical revascularization.
Journal ArticleDOI
Silent Brain Infarction and Risk of Future Stroke: A Systematic Review and Meta-Analysis.
Ajay Gupta,Ashley E. Giambrone,Gino Gialdini,Caitlin Finn,Diana Delgado,Jose A. Gutierrez,Clinton B. Wright,Alexa S. Beiser,Sudha Seshadri,Ankur Pandya,Hooman Kamel +10 more
TL;DR: SBI is present in ≈1 in 5 stroke-free older adults and is associated with a 2-fold increased risk of future stroke.